Time course of histological progression in primary biliary cirrhosis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Histological staging is used for stratification and assessment of treatment efficacy in therapeutic trials for primary biliary cirrhosis (PBC). Knowledge of the rate of progression of the histological changes would be helpful in the design (duration) and conduct of clinical trials. The histological stages were recorded for liver biopsies performed annually on 222 patients during a randomized, placebo- controlled clinical trial in which therapy with D-penicillamine (DPCA) was shown to be ineffective. These data were analyzed using a Markov model to describe the time course of histological progression in PBC. At study entry, 15 patients were stage I, 56 were stage II, 96 were stage III, and 55 were stage IV. Histological progression was observed after 1 year in 41%, 43%, and 35% of the patients, and after 2 years in 62%, 62%, and 50% of the patients who were stage I, stage II, and stage III at entry, respectively. After 4 years biopsies showed cirrhosis in 31% and 50% of the patients in stage I and stage II at entry, respectively. A minority (20%) of the precirrhotic patients showed histological stability; sustained histological regression was rarely observed (2%). Our data suggest that a majority of patients with PBC will progress histologically within 2 years. The distribution of histological stages over time may be helpful in determining the number of patients and length of time necessary to appreciate a treatment effect on histological progression in clinical trials for PBC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The median time to develop extensive fibrosis (≥F3) was 2 years.”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [53]
In the citing paper
“The median time to develop extensive fibrosis (≥F3) was 2 years.”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [54]
In the citing paper
“Several randomized trials, combined analyses, and long-term observational studies have shown that UDCA not only improves biochemical indices but also delays histologic progression and improves survival without transplantation.(53,(56)(57)(58)(59)(60)(61)(62)(63)(64)(65)(66)(67)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [53]
Citations
Cites
The Jackknife, the Bootstrap and Other Resampling Plans
Efron, B. (1982) · Society for Industrial and Applied Mathematics eBooks · doi:10.1137/1.9781611970319 · Cited by 8,120
Statistical Models Based on Counting Processes
Bry, X., Andersen, P. K., Borgan, Ø., Gill, R. D., Keiding, N., & Borgan, O. (1997) · Population (French Edition) · doi:10.2307/1534625 · Cited by 2,884
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Nineteen Dubious Ways to Compute the Exponential of a Matrix
Moler, C., & Van Loan, C. (1978) · SIAM Review · doi:10.1137/1020098 · Cited by 1,526
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Self-citationElements of the theory of Markov processes and their applications
(1960) · Journal of the Franklin Institute · doi:10.1016/0016-0032(60)90686-4 · Cited by 731
(1959) · Postgraduate Medical Journal · doi:10.1136/pgmj.45.522.305-d · Cited by 497
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Self-citation
Cited by
Bravo, A. A., Sheth, S. G., & Chopra, S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102153440706 · Cited by 2,041
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Kaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citationLindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
Self-citationCarey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735
Self-citationThe effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis
Corpechot, C., Carrat, F., Bahr, A., Chrétien, Y., Poupon, R.-E., & Poupon, R. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.009 · Cited by 390
Kumagi, T., Guindi, M., Fischer, S. E., Arenovich, T., Abdalian, R., Coltescu, C., Heathcote, J. E., & Hirschfield, G. M. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.216 · Cited by 372
“The probability of progression to biliary cirrhosis over 4 years in untreated patients with Ludwig's stage 1, stage 2 and stage 3 disease on initial biopsy has been retrospectively estimated at 31p, 50p, and 68p, respectively (”
BackgroundSelmi, C., Bowlus, C. L., Gershwin, M. E., & Coppel, R. L. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61965-4 · Cited by 334
Corpechot, C., Carrat, F., Bonnand, A.-M., Poupon, R. E., & Poupon, R. (2000) · Hepatology · doi:10.1053/jhep.2000.20240 · Cited by 316
Liver fibrosis: Pathophysiology and clinical implications
Berumen, J., Baglieri, J., Kisseleva, T., & Mekeel, K. (2021) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1499 · Cited by 259
Primary biliary cirrhosis: A 2010 update
Poupon, R. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.11.027 · Cited by 274
“750 Journal of Hepatology 201 median time to develop extensive fibrosis was 2 years and the probability of remaining in the early stage was 29% (95% confidence interval: 15–52%) after 4 years of follow-up [133,135,136].”
BackgroundHirschfield, G. M., & Heathcote, E. J. (2010) · Evidence‐Based Gastroenterology and Hepatology · doi:10.1002/9781444314403.ch32 · Cited by 261
Long‐term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis
Angulo, P., Batts, K. P., Therneau, T. M., Jorgensen, R. A., Dickson, R. E., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510290301 · Cited by 234
Self-citationNakanuma, Y., Zen, Y., Harada, K., Sasaki, M., Nonomura, A., Uehara, T., Sano, K., Kondo, F., Fukusato, T., Tsuneyama, K., et al. (2010) · Pathology International · doi:10.1111/j.1440-1827.2009.02500.x · Cited by 224
Diagnosis and Management of Primary Biliary Cholangitis
Younossi, Z. M., Bernstein, D., Shiffman, M. L., Kwo, P., Kim, W. R., Kowdley, K. V., & Jacobson, I. M. (2019) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0390-3 · Cited by 211
“Furthermore, treatment with UDCA is associated with slower histologic progression compared to untreated patients [83, 84].”
BackgroundRautiainen, H., Kärkkäinen, P., Karvonen, A., Nurmi, H., Pikkarainen, P., Nuutinen, H., & Färkkilä, M. (2005) · Hepatology · doi:10.1002/hep.20646 · Cited by 222
Kumagi, T., & Heathcote, E. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-1 · Cited by 174
“Histological progression to cirrhosis in 4 years was observed in 31%, 50% and 68% of the patients in stage 1, stage 2 and stage 3 (according to Ludwig's classification) at entry, respectively [186].”
Degott, C., Zafrani, E. S., Callard, P., Balkau, B., Poupon, R. E., & Poupon, R. (1999) · Hepatology · doi:10.1002/hep.510290444 · Cited by 174
Corpechot, C., Carrat, F., Poupon, R., & Poupon, R. (2002) · Gastroenterology · doi:10.1053/gast.2002.31880 · Cited by 169
Primary biliary cholangitis: Epidemiology, prognosis, and treatment
Trivella, J., John, B. V., & Levy, C. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000179 · Cited by 159
Diagnostic comparison of needle and wedge biopsy specimens of the liver in dogs and cats
Cole, T. L., Flood, S. N., Rowland, P. H., Valentine, B. A., Warner, K. L., & Erb, H. N. (2002) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.2002.220.1483 · Cited by 156
Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis
Springer, J., Cauch-Dudek, K., O'Rourke, K., Wanless, I. R., & Heathcote, E. J. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.00770.x · Cited by 141
You, H., Ma, X., Efe, C., Wang, G., Jeong, S.-H., Abe, K., Duan, W., Chen, S., Kong, Y., Zhang, D., et al. (2022) · Hepatology International · doi:10.1007/s12072-021-10276-6 · Cited by 133
Bezafibrate treatment: a new medical approach for PBC patients?
Kanda, T., Yokosuka, O., Imazeki, F., & Saisho, H. (2003) · Journal of Gastroenterology · doi:10.1007/s00535-002-1102-7 · Cited by 129
Donaldson, P., Agarwal, K., Craggs, A., Craig, W., James, O., & Jones, D. (2001) · Gut · doi:10.1136/gut.48.3.397 · Cited by 124
Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents
Hasegawa, S., Yoneda, M., Kurita, Y., Nogami, A., Honda, Y., Hosono, K., & Nakajima, A. (2021) · Drugs · doi:10.1007/s40265-021-01545-7 · Cited by 125
Cirrhosis, W. S. (. V. F. C. P. G. F. P. B. (2014) · Hepatology Research · doi:10.1111/hepr.12270 · Cited by 124
Santoni‐Rugiu, E., Jelnes, P., Thorgeirsson, S. S., & Bisgaard, H. C. (2005) · Apmis · doi:10.1111/j.1600-0463.2005.apm_386.x · Cited by 125
Genipin enhances Mrp2 (Abcc2)-mediated bile formation and organic anion transport in rat liver
Shoda, J., Miura, T., Utsunomiya, H., Oda, K., Yamamoto, M., Kano, M., Ikegami, T., Tanaka, N., Akita, H., Ito, K., et al. (2004) · Hepatology · doi:10.1002/hep.20003 · Cited by 111
Bowlus, C. L., Pockros, P. J., Kremer, A. E., Parés, A., Forman, L. M., Drenth, J. P. H., Ryder, S. D., Terracciano, L., Jin, Y., Liberman, A., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.09.050 · Cited by 105
Harms, M. H., Lammers, W. J., Thorburn, D., Corpechot, C., Invernizzi, P., Janssen, H. L. A., Battezzati, P. M., Nevens, F., Lindor, K. D., Floreani, A., et al. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.440 · Cited by 96
Self-citationPathogenesis of biliary fibrosis
Pinzani, M., & Luong, T. V. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.07.026 · Cited by 90
Natural history of primary biliary cirrhosis
Parés, A., & Rodés, J. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00100-4 · Cited by 89
“The rate of histologic progression of the liver disease was very low and substantially slower than that reported in other series [17,22–24].”
BackgroundResultWang, L., Han, Q., Chen, H., Wang, K., Shan, G.-L., Kong, F., Yang, Y.-J., Li, Y.-Z., Zhang, X., Dong, F., et al. (2014) · Stem Cells and Development · doi:10.1089/scd.2013.0500 · Cited by 89
Murillo Perez, C. F., Goet, J. C., Lammers, W. J., Gulamhusein, A., van Buuren, H. R., Ponsioen, C. Y., Carbone, M., Mason, A., Corpechot, C., Invernizzi, P., et al. (2018) · Hepatology · doi:10.1002/hep.29717 · Cited by 88
Self-citationSilveira, M. G., Brunt, E. M., Heathcote, J., Gores, G. J., Lindor, K. D., & Mayo, M. J. (2010) · Hepatology · doi:10.1002/hep.23637 · Cited by 87
Self-citationKaplan, M. M., Cheng, S., Price, L. L., & Bonis, P. A. L. (2004) · Hepatology · doi:10.1002/hep.20103 · Cited by 87
Guy, J. E., Qian, P., Lowell, J. A., & Peters, M. G. (2005) · Liver Transplantation · doi:10.1002/lt.20511 · Cited by 89
Okada, K., Shoda, J., Kano, M., Suzuki, S., Ohtake, N., Yamamoto, M., Takahashi, H., Utsunomiya, H., Oda, K., Sato, K., et al. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00302.2006 · Cited by 87
Time course of histological progression in primary sclerosing cholangitis
Angulo, P. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00602-4 · Cited by 64
“Regression in PSC as a measure of sampling error occurred more often than reported in another cholestatic liver disease, primary biliary cirrhosis (PBC; 15% vs 8%)”
ResultSelf-citationHepatic expression of toll-like receptor 4 in primary biliary cirrhosis
Wang, A., Migita, K., Ito, M., Takii, Y., Daikoku, M., Yokoyama, T., Komori, A., Nakamura, M., Yatsuhashi, H., & Ishibashi, H. (2005) · Journal of Autoimmunity · doi:10.1016/j.jaut.2005.05.003 · Cited by 81
Cirrhosis and autoimmune liver disease: Current understanding
Liberal, R., & Grant, C. R. (2016) · World Journal of Hepatology · doi:10.4254/wjh.v8.i28.1157 · Cited by 84
A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis
Kaplan, M. M., Schmid, C. H., Provenzale, D., Sharma, A., Dickstein, G., & McKusick, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70403-8 · Cited by 74
Proposal of a new staging and grading system of the liver for primary biliary cirrhosis
Hiramatsu, K., Aoyama, H., Zen, Y., Aishima, S., Kitagawa, S., & Nakanuma, Y. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02537.x · Cited by 71
“However, it is well known that histological changes are heterogeneous in PBC livers and sampling errors are indicated in needle liver biopsy specimens of PBC; histological lesions characterizing different stages can be seen in one liver biopsy specimen and the staging may be different in liver biopsy specimens obtaine…”
BackgroundGaloosian, A., Hanlon, C. L., Zhang, J., Holt, E. W., & Yimam, K. K. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2019.00049 · Cited by 76
“Without treatment, patients with PBC progress, on average, one histologic stage within 2 years.(59) Treatment of PBC is aimed at reducing symptoms of cholestasis, preventing fibrosis progression and avoiding complications of end-stage disease.”
BackgroundSurveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis
Silveira, M. G., Suzuki, A., & Lindor, K. D. (2008) · Hepatology · doi:10.1002/hep.22458 · Cited by 68
Self-citationTumour necrosis factor-a promoter polymorphisms in primary biliary cirrhosis
Jones, D. E. J., Watt, F. E., Grove, J. I., Newton, J. L., Daly, A. K., Gregory, W. L., Day, C. P., James, O., & Bassendine, M. F. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80067-1 · Cited by 67
Sebagh, M., Farges, O., Dubel, L., Samuel, D., Bismuth, H., & Reynes, M. (1998) · Transplantation · doi:10.1097/00007890-199805270-00008 · Cited by 68
Obeticholic acid for the treatment of primary biliary cirrhosis
Trivedi, P. J., Hirschfield, G. M., & Gershwin, M. E. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1092381 · Cited by 63
“[32, 33] Advanced histological stage is a clear determinant of poor clinical outcome and in an era where liver biopsy was the norm and effective therapy lacking, the median time to develop extensive fibrosis was ~2 years and probability of remaining in early stage disease <30% over a 4-year period.[34, 35] However, th…”
BackgroundEvaluation of Fatigue in U.S. Patients with Primary Biliary Cirrhosis
Stanca, C. M., Bach, N., Krause, C., Tandon, N., Freni, M. A., Gutierrez, J. A., Bodian, C., Lopez, J., Berk, P. D., Bodenheimer, H. C., et al. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41315.x · Cited by 62
Koch, A., Brahm, J., Antezana, C., Smok, G., & Cumsille, M. A. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80294-2 · Cited by 60
Predicting outcome in primary biliary cirrhosis
Lammers, W. J., Kowdley, K. V., & van Buuren, H. R. (2014) · Annals of Hepatology · doi:10.1016/s1665-2681(19)30838-5 · Cited by 59
“13 Since this agent does not delay histological progression, 14 this study is considered as representative of histological progression in treatment-naïve PBC patients.”
Pharmacological interventions for primary biliary cholangitis
Saffioti, F., Gurusamy, K. S., Eusebi, L. H., Tsochatzis, E., Davidson, B. R., & Thorburn, D. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011648.pub2 · Cited by 53
Treatment of autoimmune liver disease: current and future therapeutic options
Trivedi, P. J., & Hirschfield, G. M. (2013) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622313478646 · Cited by 49
3,5-Diethoxycarbonyl-1,4-Dihydrocollidine Diet: A Rodent Model in Cholestasis Research
Pose, E., Sancho‐Bru, P., & Coll, M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9420-5_16 · Cited by 54
Natural History of Primary Biliary Cholangitis in the Ursodeoxycholic Acid Era
Goel, A., & Kim, W. R. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.007 · Cited by 51
Natural History of Primary Biliary Cirrhosis
Mayo, M. J. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.012 · Cited by 51
“After 4 years, 31% of patients whose initial biopsy showed stage 1 had progressed to cirrhosis, and 50% of patients who started in stage 2 had progressed to cirrhosis [28].”
Wang, H., Xu, H., Wang, X., Wu, R., Gao, X., Jin, Q., & Niu, J. (2016) · Medicine · doi:10.1097/md.0000000000003114 · Cited by 50
Incidence, prevalence and clinical course of primary biliary cirrhosis in a Spanish community
Pla, X., Vergara, M., Gil, M., Dalmau, B., Cisteró, B., Bella, R. M., & Real, J. (2007) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e328277594a · Cited by 46
Clinical features and management of primary biliary cirrhosis
Crosignani, A. L., Battezzati, P. M., Invernizzi, P., Selmi, C. F., Prina, E., & Podda, M. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3313 · Cited by 52
PRIMARY BILIARY CIRRHOSIS AND PRIMARY SCLEROSING CHOLANGITIS
Angulo, P., & Lindor, K. D. (1999) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70084-2 · Cited by 47
Self-citationYabushita, K., Yamamoto, K., Ibuki, N., Okano, N., Matsumura, S., Okamoto, R., Shimada, N., & Tsuji, T. (2001) · Liver International · doi:10.1034/j.1600-0676.2001.210108.x · Cited by 45
Diagnosis and treatment of primary biliary cholangitis
Laschtowitz, A., de Veer, R. C., der Meer, A. J. V., & Schramm, C. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640620919585 · Cited by 44
“Within 4 years, progression towards cirrhosis was observed in 40% of patients with an early histological disease stage (stage I or II) and in 68% of patients with advanced disease (stage III).(8) In the case of cirrhosis, patients are at risk of liver failure and develop hepatocellular carcinoma at an annual rate of 3…”
BackgroundMethotrexate therapy for primary biliary cirrhosis
Bach, N. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)05841-0 · Cited by 41
Self-citationKim, H. P., Lee, E. J., Kim, Y. C., Kim, J., Kim, H. K., Park, J., Kim, S. Y., & Kim, Y. C. (2002) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.25.390 · Cited by 43
The pathology of primary biliary cirrhosis and autoimmune cholangitis
Ludwig, J. (2000) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2000.0106 · Cited by 42
Self-citationRisk Factors and Prediction of Long-term Outcome in Primary Biliary Cirrhosis
Ishibashi, H., Komori, A., Shimoda, S., Ambrosini, Y. M., Gershwin, M. E., & Nakamura, M. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.4462 · Cited by 42
D-penicillamine for primary biliary cirrhosis
Gong, Y., Klingenberg, S. L., & Gluud, C. N. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004789.pub2 · Cited by 38
Microarray Expression Profile of Circular RNAs in Plasma from Primary Biliary Cholangitis Patients
Zheng, J., Li, Z., Wang, T., Zhao, Y., & Wang, Y. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485487 · Cited by 35
Sorda, J. A., Ballerga, E. G., Barreyro, F. J., Avagnina, A., Carballo, P., de Lima, A. P., & Daruich, J. R. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16618 · Cited by 35
Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid
van Hooff, M. C., Werner, E., & van der Meer, A. J. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.01.030 · Cited by 32
Natural history and management of primary biliary cirrhosis
Kumagi, T., & Al‐Harthy, N. (2012) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s25998 · Cited by 37
Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update
Bowlus, C. L., Kenney, J. T., Rice, G. K., & Navarro, R. P. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.10-a-s.s3 · Cited by 31
Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.
Bahar, R., Wong, K. A., Liu, C. H., & Bowlus, C. L. (2018) · Europe PMC (PubMed Central) · Cited by 32
HISTOPATHOLOGY OF CHRONIC CHOLESTASIS AND ADULT DUCTOPENIC SYNDROME
Desmet, V. J. (1998) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70006-4 · Cited by 33
Primary biliary cirrhosis and autoimmune cholangiopathy
Vierling, J. M. (2004) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00132-6 · Cited by 31
Wong, G. L., Hui, A., Wong, V. W., Chan, F. K. L., Sung, J. J. �., & Chan, H. L.-Y. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.50007.x · Cited by 28
“PBC is a chronic and slowly progressive disease (11).”
BackgroundEpidemiological and economical burden of cholestatic liver disease
Mol, B., Werner, E., Culver, E. L., van der Meer, A. J., Bogaards, J. A., & Ponsioen, C. Y. (2025) · Hepatology · doi:10.1097/hep.0000000000001341 · Cited by 31
Primary biliary cirrhosis and bile acids
Corpechot, C. (2012) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/s2210-7401(12)70016-5 · Cited by 28
Treatment of Primary Biliary Cirrhosis: Therapy with Choleretic and Immunosuppressive Agents
Silveira, M. G., & Lindor, K. D. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.008 · Cited by 27
Self-citationRisk factors for hepatic decompensation in patients with primary biliary cirrhosis
Shi, T. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i7.1111 · Cited by 30
Nakagome, Y., Ueno, Y., Kogure, T., Fukushima, K., Moritoki, Y., Ridgway, W. M., Gershwin, M. E., & Shimosegawa, T. (2007) · Journal of Autoimmunity · doi:10.1016/j.jaut.2007.03.004 · Cited by 27
Natural history of primary biliary cirrhosis
Abe, M., & Onji, M. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2008.00351.x · Cited by 26
Diagnosis and management of primary biliary cirrhosis
Ali, A. H., Carey, E. J., & Lindor, K. D. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.979792 · Cited by 24
“Serial liver biopsies were assessed in 222 patients with PBC during a prospective, randomized, placebocontrolled clinical trial in which therapy with D-penicillamine was shown to be ineffective [44].”
BackgroundMethodInfluentialSelf-citationLiver fibrosis progression predicts survival in patients with primary biliary cirrhosis
Namisaki, T., Moriya, K., Noguchi, R., Kitade, M., Kawaratani, H., Yamao, J., Mitoro, A., Yoshida, M., Sawai, M., Uejima, M., et al. (2016) · Hepatology Research · doi:10.1111/hepr.12746 · Cited by 23
Increased mean platelet volume is related to histologic severity of primary biliary cirrhosis
Tahtacı, M., Yürekli, Ö. T., BOLAT, A. D., Balcı, S., Akın, F. E., Büyükaşık, N. Ş., & Ersoy, O. (2015) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000463 · Cited by 23
Chatzipantelis, P., LAZARIS, A., Kafiri, G., Papadimitriou, Κ., Papathomas, T. G., Nonni, A., & Patsouris, E. (2006) · Hepatology Research · doi:10.1016/j.hepres.2006.07.014 · Cited by 23
Jones, D. E., James, O., & Bassendine, M. F. (1998) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70007-6 · Cited by 26
Patterns of disease progression and incidence of complications in primary biliary cholangitis (PBC)
Janmohamed, A., & Trivedi, P. J. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.06.002 · Cited by 21
Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid
Boberg, K. M., Wisløff, T. F., Kjøllesdal, K. S., Støvring, H., & Kristiansen, I. S. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12435 · Cited by 21
Li, Y., Hu, C., Leng, X., Zhao, G., Li, N., & Xu, Y. (2009) · The Anatomical Record · doi:10.1002/ar.20870 · Cited by 21
“…cirrhosis; biomarker; magnetic beads; MALDI-TOF-MS Primary biliary cirrhosis (PBC) is a chronic autoimmune cholestatic liver disease characterized by progressive, nonsuppurative inflammation, and the destruction of small and medium-sized bile ducts (Locke et al., 1996; Kaplan and Gershwin, 2005).”
BackgroundMeng, J., Xu, H., Liu, X., Wu, R., & Niu, J. (2018) · Medicine · doi:10.1097/md.0000000000013431 · Cited by 17
Primary biliary cirrhosis: From bench to bedside
Kouroumalis, E., & Notas, G. (2015) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v6.i3.32 · Cited by 21
Improving prognosis in primary biliary cholangitis – Therapeutic options and strategy
Harms, M. H., van Buuren, H. R., & van der Meer, A. J. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.06.004 · Cited by 18
Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis
Angulo, P., Bartts, K. P., Therneau, T. M., Jorgensen, R. A., Dickson, E. R., & Lindor, K. D. (1999) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-199906000-00019 · Cited by 15
Self-citationJiang, X., Ya, W., Su, Z., Yang, F., Lv, H., Lin, L., & Sun, C. (2018) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2018.1449011 · Cited by 15
“and prognostic information during the follow-up period [1].”
BackgroundLiver damage in bleomycin-induced pulmonary fibrosis in mice
Vásquez-Garzón, V. R., Ramírez-Cosmes, A., Reyes-Jiménez, E., Torres, G., Hernández-García, S., Aguilar-Ruíz, S. R., Aguilar, H. T., Alpuche, J. J., Mayoral, L. P.-C., Pina-Canseco, M. D. S., et al. (2019) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-019-01690-7 · Cited by 15
Early primary biliary cirrhosis: Just delayed or different?
Lindor, K. D. (1997) · Hepatology · doi:10.1002/hep.510260135 · Cited by 16
Self-citation
Metadata
- Authors
- Locke, G. R., Therneau, T. M., Ludwig, J., Dickson, E. R., & Lindor, K. D.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- Hepatology
- Published
- 1996-01
- Volume
- 23
- Issue
- 1
- Pages
- 52-56
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2112332162
- Cited by
- 184
- References
- 30
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 8 · 2023: 2 · 2022: 6 · 2021: 7 · 2020: 9 · 2019: 11 · 2018: 13 · 2017: 9 · 2016: 5 · 2015: 6 · 2014: 4 · 2013: 4 · 2012: 5
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 7183 d)
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 34-238-07A1)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- primary biliary cirrhosis, histological progression, histological staging, liver biopsy, D-penicillamine, Markov model, disease progression rate, histological regression, clinical trial design, treatment efficacy assessment
- MeSH terms
- Biopsy, Double-Blind Method, Female, Humans, Liver, Liver Cirrhosis, Biliary, Male, Markov Chains, Middle Aged, Penicillamine, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.